Teva 4th-quarter sales and earnings in line with expectations
Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) today reported results for the quarter and the year ended December 31, 2014, which were in line with analysts’ forecasts.
Fourth quarter 2014 revenues were $5.2 billion (versus average forecasts of $5.16 billion of analysts polled by Thomson Reuters) and full year revenues were $20.3 billion. Excluding the impact of the divestment of the US generally accepted accounting principles ( OTC plants and of foreign exchange fluctuations, both fourth quarter and full year revenues grew 2% organically.
Fourth quarter 2014 non- generally accepted accounting principles (GAAP) operating income of $1.5 billion was up 10% from the fourth quarter of 2013. GAAP operating income of $0.9 billion was up 68%. Full year 2014 non-GAAP operating income of $5.7 billion was up 10% from 2013. GAAP operating income of $4.0 billion showed an increase of 140%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze